1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > PharmaPoint: Major Depressive Disorder - US Drug Forecast and Market Analysis to 2023

PharmaPoint: Major Depressive Disorder - US Drug Forecast and Market Analysis to 2023

Summary

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly’s Cymbalta, and Otsuka/BMS’s Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda’s Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

The value of the US market is expected to fall following patent expiries for Eli Lilly’s Cymbalta in 2013, Otsuka Pharmaceutical/BMS’s Abilify in 2015, and AstraZeneca’s Seroquel XR in 2017. After a period of declining sales, GlobalData estimates that the MDD market in the US will follow a steady growth trend from 2018 to 2023.

Scope

- Overview of Major depressive disorder including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Major depressive disorder market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in the US.

Table Of Contents

PharmaPoint: Major Depressive Disorder - US Drug Forecast and Market Analysis to 2023
1 Table of Contents

2 Introduction 13
2.1 Catalyst 13
2.2 Related Reports 13
2.3 Upcoming Related Reports 15
3 Disease Overview 16
3.1 Etiology and Pathophysiology 16
3.1.1 Etiology 16
3.1.2 Pathophysiology 16
3.2 Classification 18
3.3 Symptoms and Subtypes of Major Depressive Disorder 20
3.4 Prognosis 21
3.5 Quality of Life 21
4 Disease Management 22
4.1 Diagnosis and Treatment Overview 22
4.1.1 Diagnosis 22
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 23
4.1.3 Clinical Practice 24
4.2 US 27
5 Competitive Assessment 30
5.1 Overview 30
5.2 Product Profiles: Major Brands, Selective Serotonin Reuptake Inhibitors 32
5.2.1 Lexapro (Escitalopram) 32
5.2.2 Viibryd (Vilazodone) 36
5.2.3 Other Selective Serotonin Reuptake Inhibitors 39
5.3 Product Profiles: Major Brands, Serotonin-Norepinephrine Reuptake Inhibitors 43
5.3.1 Effexor (Venlafaxine) 43
5.3.2 Cymbalta (Duloxetine) 46
5.3.3 Pristiq (Desvenlafaxine) 50
5.3.4 Fetzima (Levomilnacipran) 54
5.3.5 Savella (Milnacipran) 58
5.4 Product Profiles: Major Brands, Other Antidepressants 60
5.4.1 Norepinephrine-Dopamine Reuptake Inhibitors 60
5.4.2 Noradrenaline and Specific Serotonergic Antidepressants 64
5.4.3 Monoamine Oxidase Inhibitors 68
5.4.4 Tricyclic Antidepressants 70
5.4.5 Brintellix (Vortioxetine) 72
5.5 Product Profiles: Major Brands, Antipsychotics 78
5.5.1 Abilify (Aripiprazole) 78
5.5.2 Seroquel XR (Quetiapine) 82
5.6 Other Therapeutic Classes 86
6 Unmet Needs and Opportunities 87
6.1 Overview 87
6.2 More Effective Pharmacotherapies 88
6.2.1 Unmet Needs 88
6.2.2 Gap Analysis 89
6.2.3 Opportunities 90
6.3 More Favorable Side Effect Profiles 90
6.3.1 Unmet Needs 90
6.3.2 Gap Analysis 91
6.3.3 Opportunities 91
6.4 Rapid Onset of Antidepressant Effects 92
6.4.1 Unmet Needs 92
6.4.2 Gap Analysis 92
6.4.3 Opportunities 92
6.5 Personalized Treatment Approach 93
6.5.1 Unmet Needs 93
6.5.2 Gap Analysis 94
6.5.3 Opportunities 94
7 Pipeline Assessment 95
7.1 Overview 95
7.2 Promising Drugs in Clinical Development 95
7.2.1 Brexpiprazole (OPC-34712) 98
7.2.2 Cariprazine (RGH-188) 104
7.2.3 ALKS-5461 109
7.2.4 Amitifadine (EB-1010) 114
7.2.5 GLYX-13 119
7.2.6 Tedatioxetine (Lu AA24530) 123
7.2.7 ETS6103 127
7.3 Other Drugs in Development 132
8 Market Outlook 134
8.1 US 134
8.1.1 Forecast 134
8.1.2 Key Events 138
8.1.3 Drivers and Barriers - Global Issues 138
8.1.4 Drivers and Barriers 140
9 Appendix 143
9.1 Bibliography 143
9.2 Abbreviations 148
9.3 Methodology 152
9.4 Forecasting Methodology 152
9.4.1 Diagnosed MDD Patients 152
9.4.2 Percent of Drug-Treated Patients 152
9.4.3 Drugs Included in Each Therapeutic Class 153
9.4.4 Launch and Patent Expiry Dates 153
9.4.5 General Pricing Assumptions 154
9.4.6 Individual Drug Assumptions 154
9.4.7 Generic Erosion 159
9.4.8 Pricing of Pipeline Agents 159
9.5 Physicians and Specialists Included in this Study 161
9.6 About the Authors 163
9.6.1 Analyst 163
9.6.2 Therapy Area Directors 163
9.6.3 Global Head of Healthcare 164
9.7 About GlobalData 165
9.8 Disclaimer 165

1.1 List of Tables

Table 1: Classification and Criteria of Major Depressive Disorder (DSM-IV) and Major Depressive Episode (ICD-10) 19
Table 2: Subtypes of Major Depressive Disorder 20
Table 3: Severity of Depressive Episodes according to ICD-10 and DSM-IV Diagnostic Criteria 22
Table 4: Treatment Guidelines for Major Depressive Disorder 23
Table 5: Most Prescribed Drugs for MDD by Class in the US, 2013 23
Table 6: Country Profile - US 29
Table 7: Leading Treatments for MDD, 2013 31
Table 8: Product Profile - Lexapro 33
Table 9: Safety of Lexapro - Five Most Frequently Reported Adverse Events 35
Table 10: Lexapro SWOT Analysis, 2014 35
Table 11: Product Profile - Viibryd 37
Table 12: Summary of Efficacy Results for the Primary Endpoint in Viibryd Clinical Trials 37
Table 13: Safety of Viibryd - Five Most Frequently Reported Adverse Events 38
Table 14: Viibryd SWOT Analysis, 2023 39
Table 15: Relative Frequency of Common Adverse Effects for Different SSRIs 42
Table 16: Product Profile - Effexor 44
Table 17: Effexor SWOT Analysis, 2014 46
Table 18: Product Profile - Cymbalta 48
Table 19: Cymbalta SWOT Analysis, 2023 50
Table 20: Product Profile - Pristiq 51
Table 21: Efficacy of Pristiq in short-term studies 52
Table 22: Pristiq SWOT Analysis, 2014 54
Table 23: Product Profile - Fetzima 55
Table 24: Clinical Efficacy of Fetzima from its Three Pivotal Studies 56
Table 25: Safety of Fetzima - Five Most Frequently Reported Adverse Events in Clinical Studies 57
Table 26: Fetzima SWOT Analysis, 2014 57
Table 27: Product Profile - Savella 58
Table 28: Savella SWOT Analysis, 2014 60
Table 29: Product Profile - Bupropion 62
Table 30: Safety of Bupropion - Five Most Frequently Reported Adverse Events 63
Table 31: Bupropion SWOT Analysis, 2014 64
Table 32: Product Profile - Mirtazapine 66
Table 33: Safety of Mirtazapine - Four Most Frequently Reported Adverse Events 67
Table 34: Mirtazapine SWOT Analysis, 2014 68
Table 35: MAOI SWOT Analysis, 2014 70
Table 36: TCAs SWOT Analysis, 2014 72
Table 37: Product Profile - Brintellix 74
Table 38: Efficacy of Brintellix in Six-Week to Eight-Week Clinical Trials 75
Table 39: Safety of Brintellix - Five Most Frequently Reported Adverse Events 77
Table 40: Brintellix SWOT Analysis, 2014 77
Table 41: Product Profile - Abilify 79
Table 42: Safety of Abilify - Five Most Frequently Reported Adverse Events 81
Table 43: Abilify SWOT Analysis, 2014 81
Table 44: Product Profile - Seroquel XR 83
Table 45: Efficacy of Seroquel XR as an Adjunctive Therapy to Antidepressants 84
Table 46: Safety of Seroquel XR- Five Most Frequently Reported Adverse Events 85
Table 47: Seroquel XR SWOT Analysis, 2014 85
Table 48: Summary of Minor Therapeutic Classes in MDD, 2013 86
Table 49: Unmet Needs and Opportunities in MDD 88
Table 50: Comparison of Therapeutic Classes in Development for MDD, 2013 97
Table 51: Product Profile - Brexpiprazole 100
Table 52: Safety of Brexpiprazole - Most Frequently Reported Adverse Events 102
Table 53: Brexpiprazole SWOT Analysis, 2014 104
Table 54: Product Profile - Cariprazine 106
Table 55: Cariprazine SWOT Analysis, 2014 109
Table 56: Product Profile - ALKS-5461 111
Table 57: ALKS-5461 SWOT Analysis, 2014 114
Table 58: Product Profile - Amitifadine 116
Table 59: Amitifadine SWOT Analysis, 2014 119
Table 60: Product Profile - GLYX-13 120
Table 61: GLYX-13 SWOT Analysis, 2014 123
Table 62: Product Profile - Tedatioxetine 125
Table 63: Tedatioxetine SWOT Analysis, 2014 127
Table 64: Product Profile - ETS6103 129
Table 65: ETS6103 SWOT Analysis, 2014 132
Table 66: Drugs in Development for MDD, 2014 133
Table 67: Sales Forecasts ($m) for MDD in the US, 2013-2023 136
Table 68: Key Events Impacting Sales for MDD in the US, 2013-2023 138
Table 69: MDD Market - Drivers and Barriers, 2013-2023 138
Table 70: MDD Market in the US - Drivers and Barriers, 2013-2023 140
Table 71: Key Launch Dates 153
Table 72: Key Patent Expiries 154
Table 73: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country 16

1.2 List of Figures

Figure 1: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons 18
Figure 2: Disease Management Model for Major Depressive Disorder 25
Figure 3: Major Depressive Disorder Treatment Algorithm 27
Figure 4: MDD - Phase IIb-III Pipeline, 2014 96
Figure 5: Competitive Assessment of Late-Stage Pipeline Agents in MDD, 2013-2023 97
Figure 6: Clinical and Commercial Positioning of Brexpiprazole 103
Figure 7: Clinical and Commercial Positioning of Cariprazine 108
Figure 8: Clinical and Commercial Positioning of ALKS-5461 113
Figure 9: Clinical and Commercial Positioning of Amitifadine 118
Figure 10: Clinical and Commercial Positioning of GLYX-13 122
Figure 11: Clinical and Commercial Positioning of Tedatioxetine 126
Figure 12: Clinical and Commercial Positioning of ETS6103 131
Figure 13: Sales for MDD in the US by Drug Class, 2013-2023 137

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Global Depression Partnering 2010 to 2016

Global Depression Partnering 2010 to 2016

  • $ 1495
  • Industry report
  • November 2016
  • by Currentpartnering

The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world’s leading healthcare companies. - ...

 Treatment Resistant Depression-Pipeline Insights, 2016

Treatment Resistant Depression-Pipeline Insights, 2016

  • $ 1250
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s, “ Treatment Resistant Depression-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Treatment Resistant ...

Neuromodulation Market (by Technology, Applications Segment, Region and Company) and Forecast to 2021 - Global Analysis

Neuromodulation Market (by Technology, Applications Segment, Region and Company) and Forecast to 2021 - Global Analysis

  • $ 1250
  • Industry report
  • October 2016
  • by Igate Research

The global neuromodulation market is poised to cross US$ 5 Billion mark by 2021. Neuromodulation is a technology that acts directly upon nerves. It is the alteration-or modulation-of nerve activity by ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in the UK

  • December 2016
    194 pages
  • Therapy  

    Infectious Dise...  

    Eye Disease  

  • United Kingdom  

View report >

Opioid and Anesthetics Market in Australia

  • December 2016
    5 pages
  • Opioid  

    Anesthetics  

    Analgesic  

  • Australia  

View report >

Therapy Market in Canada - Forecast

  • December 2016
    63 pages
  • Therapy  

    Monoclonal Anti...  

  • Canada  

View report >

Related Market Segments :

Depression

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.